Table 4.
Factors that influence OS in metastatic melanoma patients treated with BRAFi/MEKi -> immunotherapy—treatment sequence.
| Factor | Univariate Analysis | Multivariate Analysis | ||||
|---|---|---|---|---|---|---|
| HR | CI 95% | p-Value | HR | CI 95% | p-Value | |
| Age | 1.00 | 1.0–1.0 | 0.9848 | - | ||
| Sex | 1.14 | 0.8–1.6 | 0.4373 | - | ||
| Brain metastases 1L | 0.57 | 0.4–0.8 | 0.0310 | 0.62 | 0.4–0.9 | 0.0165 |
| Liver metastases 1L | 0.70 | 0.5–1.0 | 0.0406 | 0.88 | 0.6–1.3 | 0.4954 |
| Brain metastases 2L | 0.58 | 0.4–0.8 | 0.0011 | 0.44 | 0.3–0.6 | <0.0001 |
| Liver metastases 2L | 0.56 | 0.4–0.8 | 0.0007 | 0.69 | 0.5–1.0 | 0.0340 |
| LDH over ULN 1L | 0.61 | 0.4–0.9 | 0.0042 | 0.54 | 0.4–0.8 | 0.0018 |
| LDH over ULN 2L | 0.45 | 0.3–0.6 | <0.0001 | 0.49 | 0.3–0.7 | <0.0001 |
| Objective response in 1L | 0.79 | 0.6–1.1 | 0.1421 | 0.87 | 0.6–1.4 | 0.4326 |
| Objective response in 2L | 0.14 | 0.1–0.3 | <0.0001 | 0.13 | 0.1–0.2 | <0.0001 |
| Time to PD 1L > 6 m | 2.64 | 1.9–3.7 | <0.0001 | 2.8 | 1.9–4.1 | <0.0001 |
F, female; M, male; LDH, lactate dehydrogenase; ECOG, Eastern Cooperative Oncology Group (performance status); PD, progression disease; ORR (CR + PR), overall response rate; PD, progressive disease; 1L, first line (treatment); 2L, second line (treatment); m, months, HR, hazard ratio; CL, confidence interval.